We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people wh... Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia. Show more
- New patent would extend coverage and expand potential value of Virios’ antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses...
00018188442023FYfalseVirios Therapeutics, Inc.18330390000.0001P10YP6M000018188442023-03-182023-03-1800018188442021-12-212021-12-210001818844srt:MinimumMember2023-01-012023-12-310001818844srt:Maximu...
0001818844false00018188442024-03-012024-03-01UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 8-KCURRENT REPORTPURSUANT TO...
00018188442023FYfalseVirios Therapeutics, Inc.18330390000.0001P10YP6M000018188442023-03-182023-03-1800018188442021-12-212021-12-210001818844srt:MinimumMember2023-01-012023-12-310001818844srt:Maximu...
0001818844false00018188442024-02-292024-02-29UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORM 8-KCURRENT REPORTPURSUANT TO SECTION 13...
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1373 | 37.8863134658 | 0.3624 | 0.6288 | 0.331 | 1734512 | 0.45258254 | CS |
4 | 0.1107 | 28.4575835476 | 0.389 | 0.6288 | 0.279 | 582148 | 0.42376101 | CS |
12 | -0.0529 | -9.57292797684 | 0.5526 | 0.94 | 0.279 | 388126 | 0.45793018 | CS |
26 | -0.4303 | -46.2688172043 | 0.93 | 1.04 | 0.279 | 393297 | 0.61382893 | CS |
52 | 0.0897 | 21.8780487805 | 0.41 | 2.42 | 0.279 | 1070837 | 0.98070514 | CS |
156 | -4.8303 | -90.6247654784 | 5.33 | 9.1109 | 0.218951 | 488270 | 1.11098197 | CS |
260 | -13.2603 | -96.3684593023 | 13.76 | 14.39 | 0.218951 | 479000 | 1.59870879 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions